Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Up 300.2% in January

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 630,577 shares, a growth of 300.2% from the January 15th total of 157,548 shares. Based on an average daily trading volume, of 658,211 shares, the short-interest ratio is presently 1.0 days. Approximately 0.6% of the shares of the company are short sold. Approximately 0.6% of the shares of the company are short sold. Based on an average daily trading volume, of 658,211 shares, the short-interest ratio is presently 1.0 days.

Inventiva Stock Performance

NASDAQ IVA traded up $0.02 on Friday, hitting $6.22. The stock had a trading volume of 323,854 shares, compared to its average volume of 576,193. The firm has a 50-day moving average of $5.36 and a 200-day moving average of $4.98. Inventiva has a 52-week low of $2.46 and a 52-week high of $7.98.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Guggenheim lowered their price objective on Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Barclays started coverage on shares of Inventiva in a research note on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Wolfe Research raised shares of Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. Finally, HC Wainwright set a $24.00 price target on Inventiva and gave the stock a “buy” rating in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $16.22.

Hedge Funds Weigh In On Inventiva

A number of institutional investors have recently added to or reduced their stakes in IVA. Creative Planning bought a new stake in shares of Inventiva during the 2nd quarter valued at about $32,000. NewEdge Advisors LLC purchased a new stake in shares of Inventiva during the 3rd quarter valued at $116,000. Cerity Partners LLC bought a new stake in shares of Inventiva during the 4th quarter worth $93,000. Wealth Enhancement Advisory Services LLC raised its position in Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its position in Inventiva by 19.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after purchasing an additional 12,704 shares in the last quarter. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.